An adeno-associated virus vector efficiently and specifically transduces mouse skeletal muscle

Isao Murakami, Takamasa Takeuchi, Mayuyo Mori-Uchino, Seiichiro Mori, Takuma Fujii, Daisuke Aoki, Keiichi Nakagawa, Tadahito Kanda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Expression of a therapeutic gene in the skeletal muscle is a practical strategy to compensate a patients' insufficient circulating factor. Its clinical application requires a muscle-targeting vector capable of inducing a continuous high-level transgene expression. We modified an adeno-associated virus serotype 2 (AAV2) vector expressing luciferase from the mouse muscle creatine kinase gene promoter-enhancer (Ckm). First, AAVS1 insulator was inserted into the vector genome for transcriptional enhancement. This increased transduction of mouse quadriceps muscle by 11-fold at 4 weeks after intramuscular injection. Second, two capsid modifications were combined (21F capsid): incorporation of a segment of AAV1 capsid to produce a hybrid capsid and substitution of a tyrosine with a phenylalanine. Use of 21F capsid increased muscle transduction further by 18-fold, resulting in 200-fold higher efficacy than that of the unmodified vector. Compared with a vector having human elongation factor 1α promoter which showed similar efficacy in the muscle, this vector having Ckm transduced non-muscle organs less efficiently after intravenous administration. The AAV2 vector composed of the modified genome and capsid provides a backbone to develop a clinical vector expressing a therapeutic gene in the muscle.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalMolecular Biotechnology
Volume49
Issue number1
DOIs
Publication statusPublished - 01-09-2011
Externally publishedYes

Fingerprint

Dependovirus
Capsid
Viruses
Muscle
Skeletal Muscle
Genes
Muscles
Genome
MM Form Creatine Kinase
Peptide Elongation Factor 1
Intramuscular Injections
Quadriceps Muscle
Luciferases
Phenylalanine
Transgenes
Intravenous Administration
Tyrosine
Elongation
Substitution reactions
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering
  • Biochemistry
  • Applied Microbiology and Biotechnology
  • Molecular Biology

Cite this

Murakami, Isao ; Takeuchi, Takamasa ; Mori-Uchino, Mayuyo ; Mori, Seiichiro ; Fujii, Takuma ; Aoki, Daisuke ; Nakagawa, Keiichi ; Kanda, Tadahito. / An adeno-associated virus vector efficiently and specifically transduces mouse skeletal muscle. In: Molecular Biotechnology. 2011 ; Vol. 49, No. 1. pp. 1-10.
@article{531ee998afee45659a0ba43e82349f42,
title = "An adeno-associated virus vector efficiently and specifically transduces mouse skeletal muscle",
abstract = "Expression of a therapeutic gene in the skeletal muscle is a practical strategy to compensate a patients' insufficient circulating factor. Its clinical application requires a muscle-targeting vector capable of inducing a continuous high-level transgene expression. We modified an adeno-associated virus serotype 2 (AAV2) vector expressing luciferase from the mouse muscle creatine kinase gene promoter-enhancer (Ckm). First, AAVS1 insulator was inserted into the vector genome for transcriptional enhancement. This increased transduction of mouse quadriceps muscle by 11-fold at 4 weeks after intramuscular injection. Second, two capsid modifications were combined (21F capsid): incorporation of a segment of AAV1 capsid to produce a hybrid capsid and substitution of a tyrosine with a phenylalanine. Use of 21F capsid increased muscle transduction further by 18-fold, resulting in 200-fold higher efficacy than that of the unmodified vector. Compared with a vector having human elongation factor 1α promoter which showed similar efficacy in the muscle, this vector having Ckm transduced non-muscle organs less efficiently after intravenous administration. The AAV2 vector composed of the modified genome and capsid provides a backbone to develop a clinical vector expressing a therapeutic gene in the muscle.",
author = "Isao Murakami and Takamasa Takeuchi and Mayuyo Mori-Uchino and Seiichiro Mori and Takuma Fujii and Daisuke Aoki and Keiichi Nakagawa and Tadahito Kanda",
year = "2011",
month = "9",
day = "1",
doi = "10.1007/s12033-010-9369-z",
language = "English",
volume = "49",
pages = "1--10",
journal = "Molecular Biotechnology",
issn = "1073-6085",
publisher = "Humana Press",
number = "1",

}

Murakami, I, Takeuchi, T, Mori-Uchino, M, Mori, S, Fujii, T, Aoki, D, Nakagawa, K & Kanda, T 2011, 'An adeno-associated virus vector efficiently and specifically transduces mouse skeletal muscle', Molecular Biotechnology, vol. 49, no. 1, pp. 1-10. https://doi.org/10.1007/s12033-010-9369-z

An adeno-associated virus vector efficiently and specifically transduces mouse skeletal muscle. / Murakami, Isao; Takeuchi, Takamasa; Mori-Uchino, Mayuyo; Mori, Seiichiro; Fujii, Takuma; Aoki, Daisuke; Nakagawa, Keiichi; Kanda, Tadahito.

In: Molecular Biotechnology, Vol. 49, No. 1, 01.09.2011, p. 1-10.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An adeno-associated virus vector efficiently and specifically transduces mouse skeletal muscle

AU - Murakami, Isao

AU - Takeuchi, Takamasa

AU - Mori-Uchino, Mayuyo

AU - Mori, Seiichiro

AU - Fujii, Takuma

AU - Aoki, Daisuke

AU - Nakagawa, Keiichi

AU - Kanda, Tadahito

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Expression of a therapeutic gene in the skeletal muscle is a practical strategy to compensate a patients' insufficient circulating factor. Its clinical application requires a muscle-targeting vector capable of inducing a continuous high-level transgene expression. We modified an adeno-associated virus serotype 2 (AAV2) vector expressing luciferase from the mouse muscle creatine kinase gene promoter-enhancer (Ckm). First, AAVS1 insulator was inserted into the vector genome for transcriptional enhancement. This increased transduction of mouse quadriceps muscle by 11-fold at 4 weeks after intramuscular injection. Second, two capsid modifications were combined (21F capsid): incorporation of a segment of AAV1 capsid to produce a hybrid capsid and substitution of a tyrosine with a phenylalanine. Use of 21F capsid increased muscle transduction further by 18-fold, resulting in 200-fold higher efficacy than that of the unmodified vector. Compared with a vector having human elongation factor 1α promoter which showed similar efficacy in the muscle, this vector having Ckm transduced non-muscle organs less efficiently after intravenous administration. The AAV2 vector composed of the modified genome and capsid provides a backbone to develop a clinical vector expressing a therapeutic gene in the muscle.

AB - Expression of a therapeutic gene in the skeletal muscle is a practical strategy to compensate a patients' insufficient circulating factor. Its clinical application requires a muscle-targeting vector capable of inducing a continuous high-level transgene expression. We modified an adeno-associated virus serotype 2 (AAV2) vector expressing luciferase from the mouse muscle creatine kinase gene promoter-enhancer (Ckm). First, AAVS1 insulator was inserted into the vector genome for transcriptional enhancement. This increased transduction of mouse quadriceps muscle by 11-fold at 4 weeks after intramuscular injection. Second, two capsid modifications were combined (21F capsid): incorporation of a segment of AAV1 capsid to produce a hybrid capsid and substitution of a tyrosine with a phenylalanine. Use of 21F capsid increased muscle transduction further by 18-fold, resulting in 200-fold higher efficacy than that of the unmodified vector. Compared with a vector having human elongation factor 1α promoter which showed similar efficacy in the muscle, this vector having Ckm transduced non-muscle organs less efficiently after intravenous administration. The AAV2 vector composed of the modified genome and capsid provides a backbone to develop a clinical vector expressing a therapeutic gene in the muscle.

UR - http://www.scopus.com/inward/record.url?scp=79960951853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960951853&partnerID=8YFLogxK

U2 - 10.1007/s12033-010-9369-z

DO - 10.1007/s12033-010-9369-z

M3 - Article

C2 - 21197588

AN - SCOPUS:79960951853

VL - 49

SP - 1

EP - 10

JO - Molecular Biotechnology

JF - Molecular Biotechnology

SN - 1073-6085

IS - 1

ER -